C-Rad AB Class B (0R44) AI Stock Analysis

0 Followers

C-Rad AB Class B

(LSE:0R44)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Very low leverageDebt-to-equity of roughly 2–3% leaves C-Rad with substantial room to fund operations, invest in product development, or absorb demand weakness without heavy refinancing pressure. Growing equity also supports financial resilience and reduces dependence on external capital.

Negative Factors

Contracting revenueA shrinking top line weakens evidence of near-term demand expansion and can reduce operating leverage if the cost base does not adjust accordingly. Continued contraction would limit resources available for product investment and make future earnings growth more dependent on margin recovery.

C-Rad AB Class B (0R44) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: SEK 803.65M
Dividend Yield: 0.43%
Average Volume (3M): 3,836
Price to Earnings (P/E): 16.9
Beta (1Y): 0.27
Revenue Growth: -8.76%
EPS Growth: 103.87%
Country: UK
Employees: 98
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Specialties

C-Rad AB Class B Business Overview & Revenue Model

Company Description

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient po...

C-Rad AB Class B Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0R44 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:ALIF.B	74Outperform	SEK 21.98B	35.08	11.32%	0.81%	1.62%	63.45%
SE:SECT.B	74Outperform	SEK 63.34B	99.94	30.26%	0.40%	13.94%	5.70%
SE:XVIVO	64Neutral	SEK 6.14B	49.14	5.89%	―	17.83%	330.94%
SE:RAY.B	63Neutral	SEK 5.71B	28.82	22.61%	2.31%	3.16%	-5.78%
SE:PAX	57Neutral	SEK 1.47B	-289.64	-1.22%	―	34.05%	-144.96%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

GB:0R44 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0R44	C-Rad AB Class B	23.50	-10.37	-30.61%
SE:ALIF.B	AddLife AB Class B	184.50	0.61	0.33%
SE:PAX	Paxman AB	63.20	-0.80	-1.25%
SE:RAY.B	RaySearch Laboratories AB Class B	173.50	-32.64	-15.83%
SE:XVIVO	Xvivo Perfusion AB	201.00	27.40	15.78%
SE:SECT.B	Sectra AB Class B	326.80	36.52	12.58%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

C-Rad AB Class B AI Stock Analysis